Ocugen
-
Malvern Gene Company to Raise $115M from Convertible Notes While Dealing with Stock Decline
Malvern-based Ocugen saw its stock fall almost 20 percent after an announcement to use convertible notes to pay down existing…
-
Malvern’s Ocugen Prepping for $16.5 Million Stock Sale Weeks After Nixing Its COVID Vaccine
A Malvern-based biotechnology company known for its gene therapies and vaccines, is expecting to raise $16.5 million through a public…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
